At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 40 target
Drug / intervention
Sunvozertinib +1 moredrug
Likely dose
Sunvozertinib 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sunvozertinib Combined With Chemotherapy for EGFRm + Locally Advanced or Metastasis NSCLC Patients After EGFR-TKI Treatment Failure：Phase I/II (WU-KONG36)
In Brief
A Phase 2 clinical trial evaluating Sunvozertinib and Chemotherapy for Non Small Cell Lung Cancer. Currently recruiting, targeting 40 participants across 1 site.
Detailed Summary
To access the anti-tumor efficacy, safety and tolerability of Sunvozertinib combined with chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations who have progressed following standard TKI therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202420252026202720282029
First PostedJan 2024
Enrollment StartFeb 2024
TodayJul 2026
Primary CompletionDec 2027
Study CompletionDec 2028
First PostedJan 8, 2024
Enrollment StartFeb 29, 2024
Primary CompletionDec 30, 2027
Study CompletionDec 30, 2028
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 2.5 years agoPrimary completion in 1.5 years
Interventions
Sunvozertinibdrug
Sunvozertinib 200mg Quaquedie (QD)
Chemotherapydrug
Pemetrexed +platinum